Latest news with #brain cancer
Yahoo
5 days ago
- Health
- Yahoo
Man's Deadly Brain Tumor Vanishes After Taking Breakthrough Drug: ‘Lucky Break in a Devastating Situation'
A man with one of the deadliest forms of brain cancer is now hopeful for the future after his tumor completely disappeared thanks to a breakthrough drug. In October 2022, Ben Trotman was 40 years old when he was diagnosed with glioblastoma, a rare form of terminal cancer that kills more than 10,000 Americans a year, according to the National Brain Tumor Society. Glioblastoma, also known as GBM, has no known cure. Standard treatment involves surgery to remove the tumor (if possible), followed by radiation and chemotherapy. The disease is considered a highly invasive tumor in the central nervous system because its cells reproduce extremely quickly. Those who are diagnosed with the malignant tumor have a median survival rate of about 14 to 14.5 months. Following his diagnosis, Trotman was referred by a friend to The National Hospital for Neurology and Neurosurgery at University College London Hospitals (UCLH). There, Dr. Paul Mulholland, a consultant medical oncologist, recruited Trotman to be the first patient in his clinical trial. The trial involved him receiving the immunotherapy drug ipilimumab to treat his glioblastoma before undergoing any standard treatment. Afterward, Trotman began radiation and chemotherapy. 'The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy,' Mulholland said in a press release. The PEOPLE Puzzler crossword is here! How quickly can you solve it? Play now! Two years and eight months after being the sole participant in the clinical trial, Trotman, now 43, is tumor-free, and his scans have come back clear. 'It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumour that was initially visible on scans,' Mulholland explained. 'We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumour at bay, and it has so far, which we are delighted to see.' Mulholland added that his goal is to find a cure for the 'devastating disease' that is glioblastoma, and he's hoping to move forward with additional patients. Trotman is now married to wife Emily, and the couple welcomed daughter Mabel in April. The couple told the hospital that the clinical trial gave Trotman his life back. 'Getting this diagnosis was the most traumatic experience,' Emily said. 'We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live. Had we not met Dr. Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation.' 'We obviously don't know what the future holds, but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and I a bit of hope,' Trotman added. 'We are focused on rebuilding the life we thought we had lost and enjoying being parents.' The new father said he's hoping that his brain cancer journey will give others hope and inspire more patients to participate in the next clinical trial. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! Dame Siobhain McDonagh — member of parliament of the UK who lost her sister from glioblastoma in 2023 — led a fundraising campaign and raised more than €1 million to cover the costs of the next trial. 'My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma,' McDonagh said. 'Changing this was Margaret's final campaign and one that I have continued in her memory. I am so grateful to the many people who knew and respected Margaret who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial.' Mullholland recalled meeting Margaret. 'When I met Margaret, she said to me, 'What can I do to support you to cure this disease?'" 'I am incredibly grateful to her and to Siobhain, whose campaigning and fundraising in her sister's memory has led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis.' Read the original article on People
Fox News
5 days ago
- Health
- Fox News
Biden's alleged Ambien use, Trump health concerns and MRI death
MEDICAL MIRACLE – A man's deadly brain cancer tumor disappeared after an experimental drug trial. Continue reading… ATOMIC THREAT - Higher cancer rates have been linked to WWII radioactive waste in a Midwestern creek. Continue reading… Fox News LifestyleFox News Health
Globe and Mail
6 days ago
- Business
- Globe and Mail
NeOnc Technologies' Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on The interview will air live today at 11:00 a.m. ET. The interview comes on the heels of NeOnc's recent execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure, a key milestone toward the company's $50 million strategic partnership with Quazar Investment. This agreement, which covers the UAE and the broader GCC and MENA regions, reflects NeOnc's commitment to expanding its footprint and delivering life-saving therapies to patients worldwide. NeOnc was also recently included in the Russell Microcap Index, a milestone that aligns with the company's broader capital markets strategy to attract institutional capital, drive passive fund flows, and enhance market liquidity. 'This is an exciting time for NeOnc Technologies as we move closer to closing the $50 million partnership with Quazar Investment and advancing our mission to transform the treatment of brain cancers,' said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. 'We are honored to share our journey and achievements with Kenny Polcari's and Floorstocks' audiences.' ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc. Company Contact:
Yahoo
6 days ago
- Business
- Yahoo
NeOnc Technologies' Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on The interview will air live today at 11:00 a.m. ET. The interview comes on the heels of NeOnc's recent execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure, a key milestone toward the company's $50 million strategic partnership with Quazar Investment. This agreement, which covers the UAE and the broader GCC and MENA regions, reflects NeOnc's commitment to expanding its footprint and delivering life-saving therapies to patients worldwide. NeOnc was also recently included in the Russell Microcap Index, a milestone that aligns with the company's broader capital markets strategy to attract institutional capital, drive passive fund flows, and enhance market liquidity. 'This is an exciting time for NeOnc Technologies as we move closer to closing the $50 million partnership with Quazar Investment and advancing our mission to transform the treatment of brain cancers,' said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. 'We are honored to share our journey and achievements with Kenny Polcari's and Floorstocks' audiences.' ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc. Company Contact: info@ Investor Contact: James Carbonara Hayden IR (646)-755-7412 James@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 days ago
- Business
- Associated Press
NeOnc Technologies' Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. ( NTHI ), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on The interview will air live today at 11:00 a.m. ET. The interview comes on the heels of NeOnc's recent execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure, a key milestone toward the company's $50 million strategic partnership with Quazar Investment. This agreement, which covers the UAE and the broader GCC and MENA regions, reflects NeOnc's commitment to expanding its footprint and delivering life-saving therapies to patients worldwide. NeOnc was also recently included in the Russell Microcap Index, a milestone that aligns with the company's broader capital markets strategy to attract institutional capital, drive passive fund flows, and enhance market liquidity. 'This is an exciting time for NeOnc Technologies as we move closer to closing the $50 million partnership with Quazar Investment and advancing our mission to transform the treatment of brain cancers,' said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. 'We are honored to share our journey and achievements with Kenny Polcari's and Floorstocks' audiences.' ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc. Company Contact: [email protected] Investor Contact: James Carbonara Hayden IR (646)-755-7412 [email protected]
